ADAR1 Capital Management »

Alkermes shares owned by ADAR1 Capital Management

Quarter-by-quarter ownership of Alkermes (ALKS) shares owned by ADAR1 Capital Management from 13F filings

Historical chart of ADAR1 Capital Management investment in Alkermes

Tip: Access up to 7 years of quarterly data

All positions including Alkermes held by ADAR1 Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Alkermes by ADAR1 Capital Management

Quarter filed Position value Share count Share price at filing
2024-03-31 $4.2M 157k 27.07

More positions owned by ADAR1 Capital Management

Alnylam Pharmaceuticals (ALNY)
Ea Series Trust Alpha Arch 1-3 (BOXX)
Roivant Sciences SHS (ROIV)
Spdr S&p 500 Etf Tr Tr Unit Put Option (SPY)
Protagonist Therapeutics (PTGX)
Cytokinetics Com New (CYTK)
Keros Therapeutics (KROS)
Royalty Pharma Shs Class A (RPRX)
Bridgebio Pharma (BBIO)
Merrimack Pharmaceuticals In Com New
Ascendis Pharma A/s Sponsored Adr (ASND)
Arbutus Biopharma (ABUS)
Avrobio Ord (AVRO)
Beigene Sponsored Adr (BGNE)
Invesco Qqq Tr Unit Ser 1 Put Option (QQQ)

View all positions for ADAR1 Capital Management

Top funds holding Alkermes

BlackRock
Vanguard Group
T. Rowe Price Associates
State Street Corporation
Renaissance Technologies
Baker Bros. Advisors
Geode Capital Management
Deep Track Capital
PRIMECAP Management Company
Dimensional Fund Advisors
Armistice Capital
Bank of New York Mellon
Charles Schwab Investment Management
American Century Companies
Morgan Stanley

View all funds holding Alkermes